Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the
safety and tolerability of ACT-293987 in patients with PAH who participated in the
double-blind study AC-065A302 (GRIPHON)
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
This is a single-center, double-blind, randomized, placebo- and positive-controlled,
double-dummy, parallel-group, multiple-dose, up-titration study with a nested cross-over
comparison between moxifloxacin and placebo in healthy male and female subjects. The primary
objective is to demonstrate that selexipag and its metabolite ACT-333679 do not have an
effect on cardiac repolarization exceeding the threshold of regulatory concern, at two
orally administered dose levels (800 and 1600 μg twice daily) in healthy male and female
subjects. Moxifloxacin is included as a positive control.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.